26.02.2016 • News

Bayer Mum on Covestro Drawdown Plan

Bayer has refused to be drawn on when it plans to reduce the 69% stake it holds in Covestro, the former Bayer MaterialScience, following the flotation of 31% on the stock market in September 2015.

In response to questions at the annual results press conference in Leverkusen on Feb. 25, the German group’s chief financial officer, Johannes Dietsch, said there is no current timetable for a drawdown. However, he stressed that the former Bayer subgroup is purely a financial investment.

A complete pullback is still on track for the medium term, Dietsch said.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.